Research News 5


Research News

1 | 2 | 3 | 4 | 5

  • Remembering Dr. Joseph Sonnabend, Early Pioneer on AIDS

    Dr. Sonnabend was a co-founder of the AIDS Medical Foundation, amfAR’s predecessor.

  • Prospects for an HIV/AIDS Cure: Opinions of People with HIV and Their Healthcare Providers

    The authors concluded that educational strategies tailored specifically to each group are required to increase understanding of HIV cure research and the role of ATI.

  • Mining the Blood for Markers of the Reservoir

    The authors concluded that “the development of these tools may represent simple biomarkers for the rapid evaluation of changes in viral replication outside of the blood and changes in the reservoir size.”

  • HIV Reservoirs in the Blood and Gut Respond Differently to Virus Activators

    The authors conclude that “it will be critical to evaluate the efficacy of LRAs in both blood and tissues” in order to develop more effective therapeutics in HIV cure strategies.

  • The Past, Present, and Future of HIV Reservoir Cells

    Research Question The HIV reservoir consists of HIV-infected cells that are difficult to characterize because to date they have been indistinguishable from uninfected cells. Once the HIV inside infected cells is activated, many of the surface and interior characteristics change. While activated reservoir cells are easier to identify and isolate from blood samples, these fundamental…

  • A Conversation with the San Francisco Patient

    Loreen Willenberg is an elite controller (EC) – one of the rare individuals who control HIV infection without antiretroviral therapy. ECs were recently described in new and unprecedented detail in the prestigious journal Nature. Loreen was among the ECs the researchers studied. For all intents and purposes, she may be considered “cured” of HIV. Loreen…

  • Molecular Pathways to an HIV Cure

    The authors concluded that the differences they identified “could provide the HIV cure field with vital biological clues into the molecular pathways involved in viral persistence.”

  • New Study Takes Deep Dive into Elite Control

    Armed with this new vision of what one kind of cure might look like, researchers will now aim to induce the immune systems of non-controllers to bring about the same result.

  • Research Update: Pioneering Clinical Trial Gets Underway

    A unique and potentially groundbreaking clinical trial led by researchers at the amfAR Institute for HIV Cure Research is underway. The first participant received the first injection on August 13. The study will test a combination of agents in an effort to induce post-treatment control in people living with HIV. The complex, multi-stage trial is…

  • Exploring Cell Proteins That Block HIV

    Research Question Evolution has insured that many mammals—from mice to humans—have cell proteins that can prevent infection by certain viruses, including HIV. One of the most potent of these proteins, identified two decades ago, is APOBEC3G. Unfortunately for humans, HIV has evolved protection—a viral protein that prevents APOBEC3G from attacking HIV in humans, though not…

  • How Does the Immune System Recover After a Stem Cell Transplant?

    Based on a small number of patients, “highlights how little we know about the clinical course post-transplant for HIV-positive persons,” arguing for more research focused on this population.

  • Why Do HIV Reservoirs Persist After Stem Cell Transplants?

    Researchers studied 16 HIV-positive individuals on ART who underwent stem cell transplants.

  • Does ART Adequately Reach Tissue Reservoirs of HIV?

    This may contribute to the persistence of HIV reservoirs and viral rebound during analytic treatment interruption.

  • Probing the Provirus

    The decrease in intact provirus could suggest that despite potent ART, the immune system might be able to differentiate between cells infected with intact provirus and those with defective provirus.

  • New Methods to Reverse HIV Latency

    Immune checkpoint blockade is “an attractive option” to move into the clinic, as both a potential method of reversing the latent state of HIV and a strategy to boost T cell activity against HIV.

1 | 2 | 3 | 4 | 5